The subacute period of coronavirus infection is a 4- to-12-week period after acute illness associated with the SARS-CoV-2 infection. A range of bronchopulmonary symptoms in the subacute period of COVID-19 includes cough, shortness of breath, reduced exercise tolerance, which, in turn, worsens the patient’s quality of life. Despite all the achievements of modern medicine, there is still no exact understanding of the mechanisms of this condition. There are also limitations of current patients’ treatments. The successful use of exogenous surfactant in the acute period of SARS-CoV-2 infection has become the starting point in the search for new therapeutic tools for this category of patients. The paper describes a clinical observation with the use of inhaled therapy with surfactant 150 mg/day for 7 days in a patient who underwent COVID-associated pneumonia with persistent ventilation disorders, decreased exercise tolerance, and characteristic changes identified due to the multispiral computed tomography examination. The treatment included the use of the Russian-manufactured surfactant (tauractant), a lyophilisate for suspension for endotracheal, endobronchial and inhalation administration, 75 mg vials. The drug is sourced from bovine lungs, refers to ATC R07AA30 (therapeutic combinations comprising pulmonary surfactants); pharmacotherapeutic group: surfactant. The studied treatment demonstrated the efficacy and safety of administration in this category of patients, and also ensured the disease control and improved quality of life.